PEOPLE ON THE MOVE
Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, a biotech producing kinase inhibitor treatments targeting tumour cells and their microenvironment, has made Tucker Kelly CEO.
“This is an exciting time to be joining Deciphera as the company’s pipeline of kinase inhibitor therapies continue to advance and show promise as important medicines across a range of cancers,” said Kelly. “Deciphera has the potential to be a game-changer in the oncology space with its unique approach to developing improved kinase inhibitor treatments that prevent tumor cells from thriving and spreading.”
Before joining Deciphera, Kelly was Chief Financial Officer of AdvanDx, a private molecular diagnostics company. He has also been Chief Financial Officer of deCODE Genetics and Critical Therapeutics, and worked in investment banking.
